Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$119.00K$119.00K−67.4% vs Q2 2022 Net Income-$98.51M-$98.51MN/M vs Q2 2022 EPS Diluted-$0.81-$0.81N/M vs Q2 2022 Operating Income-$106,050,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$70,104,000N/M Margins · derivedOperating margin-89117.6%−67799.6 pt vs Q2 2022
Net margin-82777.3%−61739.5 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 8, 2023 · 39 d after period end